cefotaxime (claforan) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefotaxime sodium is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It’s a 3rd Generation Cephalosporin that is FDA approved for the treatment of lower respiratory tract infections, genitourinary infections, gynecologic infections, bacteremia/septicemia, skin and skin structure infections, intra-abdominal infections, bone and/or joint infections and central nervous system infections. The bactericidal activity of cefotaxime sodium results from inhibition of cell wall synthesis. Cefotaxime sodium has in vitro activity against a wide range of gram-positive and gram-negative organisms. Cefotaxime sodium has a high degree of stability in the presence of ß-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics. Common adverse reactions include injection site pain, injection site phlebitis, rash, diarrhea, vomiting. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.   NCATS

Chemistry

  • SMILES: CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
  • InChIKey: GPRBEKHLDVQUJE-QSWIMTSFSA-N
  • Mol. Mass: 455.47
  • ALogP: -0.62
  • ChEMBL Molecules:
    cefotaxime  
    cefotaxime sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$1.2420 - $1.8336
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(6r,7r)-3-acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid | (6r,7r)-3-(acetoxymethyl)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | (6r,7r,z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid | cefcil | cefotaxim | cefotaxima | cefotaxime | céfotaxime | cefotaxime sodium | cefotaxime sodium salt | cefotaximum | cephotaxime | claforan | hr-756 | pretor | ru-24756

Organizations (45)

Research & Development (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (33)

Approved Indications (12)


 

Bacteremia (approved 1981)

Bone Diseases, Infectious (approved 1981)

Central Nervous System Infections (approved 1981)

Endocarditis

Genital Diseases, Female (approved 1981)

Gonorrhea (approved 1981)

Infections

Intraabdominal Infections (approved 1981)

Pneumonia

Respiratory Tract Infections (approved 1981)

Skin Diseases, Bacterial (approved 1981)

Urinary Tract Infections (approved 1981)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Antibiotic Prophylaxis (Phase 3)

Appendicitis (Phase 2)

Bacteremia (Phase 2)

Bacterial Infections (Phase 1)

Brain Injuries (Phase 1)

Bronchopulmonary Dysplasia (Phase 2)

Cerebral Intraventricular Hemorrhage (Phase 2)

COVID-19 (Phase 4)

Critical Illness (Phase 4)

Drug Resistance, Bacterial (Phase 4)

Enterocolitis, Necrotizing (Phase 2)

Fibrosis (Phase 4)

Focus Groups (Phase 1)

Ileum (Phase 2)

Leukomalacia, Periventricular (Phase 2)

Liver Cirrhosis (Phase 4)

Lung Diseases (Phase 2)

Meningitis, Bacterial (Phase 4)

Peritonitis (Phase 4)

Pneumonia, Ventilator-Associated (Phase 4)

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial Organizations: 34

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue